Calypte Biomedical just got approval for a urine-based HIV-1 confirmatory test, showing unbelievers that urine-based assays can be as sensitive--and even more sensitive--than traditional blood-based tests. Since the test's less dangerous for health care workers to handle, the company expects its fortunes to improve dramatically.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.